1-methyl-2,5-dimethylene-2,5-dihydropyrrole

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯
• 英文名称: 1-methyl-2,5-dimethylene-2,5-dihydropyrrole
• 英文别名: N-methyl-2,5-dimethylene-2,5-dihydropyrrole；1-methyl-2,5-dimethylidenepyrrole
• 化学式: C₇H₉N
• 分子量: 107.155
• InChiKey: WZRMCSOGHQLRCW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  8
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  3.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  1,5-二甲基-2-吡咯甲腈 在 lithium aluminium tetrahydride 、 三乙胺 作用下， 以 乙醚 为溶剂， 反应 20.0h， 生成 1-methyl-2,5-dimethylene-2,5-dihydropyrrole
  参考文献：
  名称：

  Tseng, Pen-Wen; Chou, Chin-Hsing, Journal of the Chinese Chemical Society, 1994, vol. 41, # 5, p. 579 - 584

  摘要：

  DOI：

文献信息

• SUBSTITUTED OR UNSUBSTITUTED ALLYL GROUP-CONTAINING MALEIMIDE COMPOUND, PRODUCTION METHOD THEREFOR, AND COMPOSITION AND CURED PRODUCT USING SAID COMPOUND
  申请人：DIC Corporation

  公开号：EP3466993A1

  公开（公告）日：2019-04-10

  The present invention provides a compound having a low melting point and having excellent heat resistance. Disclosed is a substituted or unsubstituted allyl group-containing maleimide compound represented by the following Formula (1) in which n and m each independently represent an integer from 1 to 5; Aly represents a group containing a substituted or unsubstituted allyl group and represented by the following Formula (2) (at this time, in Formula (2), Z represents a direct bond or a hydrocarbon group having 1 to 10 carbon atoms which may have a substituent; and R1, R2, and R3 each independently represent a hydrogen atom or a methyl group); MI represents a maleimide group represented by the following Formula (3) (at this time, in Formula (3), R4 and R5 each independently represent a hydrogen atom or a methyl group); and A represents a structure having two benzene rings and represented by the following Formula (4-1) or (4-2) (at this time, each benzene ring may have a substituent; and X represents a direct bond or a divalent linking group):

  本发明提供了一种具有低熔点和优异耐热性的化合物。本发明公开了由下式（1）表示的含取代或未取代烯丙基的马来酰亚胺化合物，其中 n 和 m 各自独立地代表 1 至 5 的整数；Aly 代表含有取代或未取代烯丙基的基团，并由下式（2）表示（此时，在式（2）中，Z 代表直接键或具有 1 至 10 个碳原子的烃基，该烃基可能具有取代基；R1、R2 和 R3 各自独立地代表一个氢原子或一个甲基）；MI 代表马来酰亚胺基团，由下式（3）表示（此时，在式（3）中，R4 和 R5 各自独立地代表一个氢原子或一个甲基）；以及 A 代表具有两个苯环的结构，由下式（4-1）或（4-2）表示（此时，每个苯环可具有一个取代基；X 代表直接键或二价连接基）：
• Antibody drug conjugates
  申请人：Pharma Mar, S.A.

  公开号：US11224663B2

  公开（公告）日：2022-01-18

  Drug conjugates of formula [D-(X)b-(AA)w-(L)-]n-Ab wherein: D is a drug moiety having the following formula (I) or a pharmaceutically acceptable salt, ester, solvate, tautomer or stereoisomer thereof, wherein: A is selected from (II) and (III) R1, R2 and R3 is H, ORa, OCORa, OCO—ORa, alkyl, alkenyl, alkynyl, etc.; R3′ is, CORa, COORa, CONRaRb, etc; each of R4 to R10 and R12 is alkyl, alkenyl or alkynyl; R11 is H, CORa, COORa, alkyl, alkenyl or alkynyl, or R11 and R12+N+C atoms to which they are attached may form a heterocyclic group; each of R13 and R14 is H, CORa, COORa, alkyl, alkenyl or alkynyl; each Ra and Rb is H, alkyl, alkenyl, alkynyl, etc.; each dotted line represents an optional additional bond; X is an extending group; AA is an amino acid unit; L is a linker group; w is 0 to 12; b is 0 or 1; A bis a moiety comprising at least one antigen binding site, and n is the ratio of the group [D-(X)b-(AA)w-(L)-] to the moiety comprising at least one antigen binding site and is in the range from 1 to 20, are useful in the treatment of cancer.

  式[D-(X)b-(AA)w-(L)-]n-Ab 的药物共轭物 其中：D 是具有下式(I)的药物分子或其药学上可接受的盐、酯、溶液剂、同系物或立体异构体， 其中：A选自(II)和(III) R1、R2和R3是H、ORa、OCORa、OCO-ORa、烷基、烯基、炔基等。R3′是 CORa、COORa、CONRaRb 等；R4 至 R10 和 R12 各自是烷基、烯基或炔基；R11 是 H、CORa、COORa、烷基、烯基或炔基，或 R11 和 R12+N+C 所连接的原子可形成杂环基团；R13 和 R14 各为 H、CORa、COORa、烷基、烯基或炔基； Ra 和 Rb 各为 H、烷基、烯基或炔基等。；每条虚线代表一个任选的附加键；X 是一个延伸基团；AA 是一个氨基酸单元；L 是一个连接基团；w 是 0 至 12；b 是 0 或 1；A 之二是包含至少一个抗原结合位点的分子，n 是[D-(X)b-(AA)w-(L)-]与包含至少一个抗原结合位点的分子之比，在 1 至 20 的范围内。
• Auristatin drug linker conjugates
  申请人：Seattle Genetics, Inc.

  公开号：EP2842575B1

  公开（公告）日：2017-09-27
• Biomedical devices having improved surface characteristics
  申请人：Winterton Lynn Cook

  公开号：US20080129956A1

  公开（公告）日：2008-06-05

  Biomedical devices, such as ophthalmic lenses, and methods of making such devices having a surface coating including at least one polyionic layer. A preferred method involves spray coating a polycationic material onto a core lens, rinsing and drying the lens, followed by spray coating a polyanionic material, rinsing and drying. The coating process may be applied a plurality of times to achieve a multi-layer coating on the lens surface. A particularly preferred embodiment is a contact lens comprising a highly oxygen permeable hydrophobic core coated with a 5 to 20 bilayers of hydrophilic polyionic materials.
• Biomedical device having improved surface characteristics
  申请人：Winterton Lynn Cook

  公开号：US20090288369A1

  公开（公告）日：2009-11-26

  Biomedical devices, such as ophthalmic lenses, and methods of making such devices having a surface coating including at least one polyionic layer. A preferred method involves spray coating a polycationic material onto a core lens, rinsing and drying the lens, followed by spray coating a polyanionic material, rinsing and drying. The coating process may be applied a plurality of times to achieve a multi-layer coating on the lens surface. A particularly preferred embodiment is a contact lens comprising a highly oxygen permeable hydrophobic core coated with a 5 to 20 bilayers of hydrophilic polyionic materials.